Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis patients may get heart protection from simple amino acid infusion

NCT ID NCT07392697

Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving amino acids through the dialysis machine twice a week for a year can help protect the heart and blood vessels in people with kidney failure. About 120 adults on stable dialysis will receive either amino acids or a placebo (saline). Researchers will track deaths, heart problems, and blood vessel health to see if this simple addition can improve survival and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Diagnosis of end-stage renal disease (ESRD) and undergoing maintenance hemodialysis (HD) or online hemodiafiltration (HDF). * On a stable dialysis regimen for a minimum of 90 consecutive days prior to enrollment. * Serum albumin level ≥30 g/L. * Documented dialysis adequacy: single-pool Kt/V (spKt/V) \> 1.2. * Able to understand study procedures and provide written informed consent. Exclusion Criteria: * Administration of parenteral amino acids or intravenous nutrition within the past 90 days. * Severe hypertension (e.g., SBP \>180 mmHg despite antihypertensive therapy). * Advanced liver disease classified as Child-Pugh class C. * Diagnosis of active malignancy or cancer treatment within the last 5 years. * Current participation in another interventional study or within the past 30 days. * Pregnant or breastfeeding women. * Psychiatric or cognitive impairment that interferes with informed consent or study compliance. * Life expectancy \<12 months due to unrelated comorbidities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular calcification are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular calcification Chronic kidney disease requiring chronic dialysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Haukeland Central Hospital

    Bergen, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.